The stock of Prime Medicine Inc (PRME) has seen a 60.74% increase in the past week, with a 194.70% gain in the past month, and a 141.61% flourish in the past quarter. The volatility ratio for the week is 18.19%, and the volatility levels for the past 30 days are at 14.66% for PRME. The simple moving average for the last 20 days is 77.93% for PRME’s stock, with a simple moving average of 48.72% for the last 200 days.
Is It Worth Investing in Prime Medicine Inc (NASDAQ: PRME) Right Now?
The 36-month beta value for PRME is at 2.32. Analysts have varying views on the stock, with 6 analysts rating it as a “buy”, 2 rating it as “overweight”, 4 as “hold”, and 0 as “sell”.
The public float for PRME is 51.64M, and currently, shorts hold a 35.79% of that float. The average trading volume for PRME on July 07, 2025 was 2.56M shares.
PRME stock’s latest price update
Prime Medicine Inc (NASDAQ: PRME)’s stock price has soared by 25.08% in relation to previous closing price of $3.11. Nevertheless, the company has seen a gain of 60.74% in its stock price over the last five trading days. globenewswire.com reported 2025-07-04 that MONTREAL, July 04, 2025 (GLOBE NEWSWIRE) — Prime Drink Group Corp. (CSE: PRME) (“Prime”) announces that it has changed its auditors from MNP LLP (“Former Auditor”) to Horizon Assurance LLP (“Successor Auditor”). The Former Auditor resigned as the auditor of the Company on its own initiative effective June 25, 2025, and the board of directors of the Company appointed the Successor Auditor as the Company’s auditor effective June 30, 2025, until the next Annual General Meeting of the Company.
Analysts’ Opinion of PRME
Many brokerage firms have already submitted their reports for PRME stocks, with Citigroup repeating the rating for PRME by listing it as a “Neutral”. The predicted price for PRME in the upcoming period, according to Citigroup is $1.50 based on the research report published on May 27, 2025 of the current year 2025.
JMP Securities gave a rating of “Mkt Outperform” to PRME, setting the target price at $10 in the report published on December 10th of the previous year.
PRME Trading at 127.33% from the 50-Day Moving Average
After a stumble in the market that brought PRME to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -42.37% of loss for the given period.
Volatility was left at 14.66%, however, over the last 30 days, the volatility rate increased by 18.19%, as shares surge +190.07% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +121.63% upper at present.
During the last 5 trading sessions, PRME rose by +63.02%, which changed the moving average for the period of 200-days by +5.48% in comparison to the 20-day moving average, which settled at $2.19. In addition, Prime Medicine Inc saw -26.33% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PRME starting from Liu David R., who purchase 21,000 shares at the price of $2.52 back on Jun 30 ’25. After this action, Liu David R. now owns 20,240,945 shares of Prime Medicine Inc, valued at $52,830 using the latest closing price.
Liu David R., the 10% Owner of Prime Medicine Inc, purchase 21,000 shares at $2.16 during a trade that took place back on Jun 23 ’25, which means that Liu David R. is holding 20,219,945 shares at $45,402 based on the most recent closing price.
Stock Fundamentals for PRME
Current profitability levels for the company are sitting at:
- -4.96% for the present operating margin
- 0.96% for the gross margin
The net margin for Prime Medicine Inc stands at -4.85%. The total capital return value is set at -0.7%. Equity return is now at value -115.21%, with -63.17% for asset returns.
Based on Prime Medicine Inc (PRME), the company’s capital structure generated 0.53 points at debt to capital in total, while cash flow to debt ratio is standing at -0.86.
Currently, EBITDA for the company is -196.34 million with net debt to EBITDA at -0.15. When we switch over and look at the enterprise to sales, we see a ratio of 12.97. The receivables turnover for the company is 2448.24for trailing twelve months and the total asset turnover is 0.13. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.78.
Conclusion
In conclusion, Prime Medicine Inc (PRME) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
